PS PeptideSuppliers.org Finding the right peptide supplier for you
Cagrilintide reference image
View supplier listing 10% off with code IRONMAN
Peptide guide

Cagrilintide Peptide Guide & Supplier Listing Notes

Long-acting amylin analog

Amylin analog / appetite-regulation research

GLP and metabolic research compounds Educational guide Supplier transparency
Back to directory Compare supplier pages
Educational disclaimer

Informational reference only

This page is for educational and informational purposes only. PeptideSuppliers.org does not sell peptides, provide medical advice, or recommend human use.

Overview

Cagrilintide overview

Cagrilintide is a long-acting amylin analog. Published research most often places it within obesity, appetite regulation, and combination research with semaglutide.

The literature around Cagrilintide is usually interpreted through mechanism, study design, and compound identity. Closely related analogs, shorthand labels, and supplier naming conventions can make those distinctions especially important when comparing papers, trial records, and catalog listings.

Investigational in many contexts; track trials and publications. This broader context helps separate established findings from early-stage signals and keeps the compound anchored to the evidence base rather than to marketing language.

Research snapshot

Quick research reference

Research Category: Metabolic Research

Research Status: Investigational in many contexts; track trials and publications.

Common Areas Studied:

  • Obesity, appetite regulation, combination with semaglutide

Related Compounds:

History

Where the compound came from and why researchers keep returning to it.

The history of Cagrilintide is easiest to understand as part of a broader research line rather than as a single isolated listing. Connect to amylin biology and combination approaches to metabolic research.

That history is important because it shows what problem researchers were trying to solve, what earlier compounds shaped the field before Cagrilintide gained attention, and why the compound continues to be discussed in relation to later studies or newer analogs.

For amylin analogs specifically, that timeline runs through pramlintide's approval as a diabetes adjunct, decades of amylin-receptor biology, and now the newer wave of long-acting analogs designed for less frequent dosing. Cagrilintide sits in that newer wave, which is why comparisons to pramlintide come up so often in the literature.

Mechanism of Action

Receptors, pathways, and the biological logic that shapes the research conversation.

Cagrilintide is studied for activity at amylin receptor pathways, with research interest in appetite and satiety signaling as a complementary pathway to GLP-1 research. This is the core biological reason Cagrilintide is discussed alongside compounds such as semaglutide, tirzepatide, retatrutide, and other amylin analogs like pramlintide.

For Cagrilintide, that means tracking how amylin receptor activation in the area postrema and related brainstem regions translates into reduced food intake and slower gastric emptying, rather than assuming satiety effects observed in animal models transfer directly to any given human dosing pattern.

Amylin analogs also get grouped loosely with GLP-1 and GIP agonists in casual marketing copy even though the receptor systems are distinct. Cagrilintide's amylin-receptor activity is worth keeping separate from incretin-pathway compounds like semaglutide or tirzepatide when reading mechanism sections, even in papers that study them together.

Early cagrilintide work centered on whether amylin-pathway activation alone could produce meaningful weight change; more recent studies have shifted toward combination dosing with semaglutide and comparative efficacy against single-pathway agonists, which is the direction most current trial activity is headed.

Research Areas

The main research domains where this compound appears most often.

Research area

Obesity

Research in this area usually tracks body weight, adiposity, energy intake, and metabolic adaptation rather than treating obesity as a single uniform endpoint.

Research area

appetite/satiety

Appetite-related work usually centers on satiety signaling, food intake, gastric-emptying effects, and other pathways that shape feeding behavior in experimental models.

Research area

Combination research with semaglutide

Published work in this area varies by model, endpoint, and stage of development, so the most useful reading approach is to focus on the specific outcomes each study actually measures.

Research area

Body-weight endpoints

Endocrine studies in this category usually track growth-hormone signaling, IGF-1 response, pituitary pathways, or related hormone-axis dynamics.

Animal studies

What preclinical work has emphasized

Preclinical amylin-analog work has examined satiety and metabolic endpoints in animal models. This part of the literature often sets the first expectations around mechanism, tissue effects, or metabolic signaling, but those early signals need to be read with the normal limits of preclinical work in mind.

Rodent models remain the primary source of cagrilintide's preclinical satiety and food-intake data, with dosing frameworks that don't map directly onto the combination regimens used in later human trials. That gap is one reason preclinical satiety signals should be read as directional rather than predictive of trial-scale effect size.

The most useful preclinical summaries specify whether the model tested cagrilintide alone or in combination with a GLP-1 agonist, since the two designs answer different questions about the amylin pathway's independent contribution.

Human studies

How much human evidence exists

Human research includes investigational obesity and combination studies alongside semaglutide. When human data do exist, the best summaries distinguish the type of study being discussed, the population under investigation, and the limits of what the results can show.

Cagrilintide's human evidence base leans heavily on combination trials with semaglutide, so isolating the amylin-only contribution from published human data is harder than it looks. Readers should note whether a given trial tested cagrilintide as a monotherapy arm or only as part of a fixed-ratio combination.

Even with several completed combination trials, cagrilintide alone has not gone through the same length of human study as semaglutide, and that gap in maturity is worth keeping in view rather than treating the two compounds as equally established.

Current research status

Where the research stands now

Investigational in many contexts; track trials and publications. For Cagrilintide, the current research picture should be read as a snapshot rather than a final verdict, because publication timelines, trial readouts, and category language can shift quickly.

Cagrilintide's visibility has grown quickly alongside GLP-1 interest generally, but the compound's own regulatory pathway is still behind semaglutide's, particularly for solo (non-combination) use. Coverage that treats it as equivalently mature is getting ahead of the trial record.

ClinicalTrials.gov listings for cagrilintide/semaglutide combination programs are the most direct way to check how far the compound has progressed toward late-stage trials versus earlier-phase amylin-pathway work.

Browse suppliers Open peptide directory Read education guides Best peptide suppliers

Related Compounds

Closely related compounds frequently discussed within the same research category.

Semaglutide Tirzepatide Retatrutide
Supplier considerations

How to read supplier pages more carefully

Verify identity, purity, storage guidance; avoid protocol-like combo language. In this context, the main issue is documentation quality rather than promotional language.

For Cagrilintide, documentation quality starts with naming discipline. If a listing uses shorthand, category labels, or adjacent compound references, the exact compound identity should still be easy to follow. COAs, third-party testing notes, and batch references should reinforce that naming rather than complicate it.

Amylin analogs like cagrilintide are typically handled as lyophilized peptide products requiring refrigerated storage before reconstitution, so supplier pages that skip storage and stability language leave out a detail that matters more here than it would for small-molecule compounds.

  • Look for batch-specific COAs instead of generic laboratory files reused across many listings.
  • Check whether the product name, concentration language, and batch references stay consistent from page to page.
  • Read storage and handling notes alongside the document links rather than treating the headline purity claim as enough.
  • Prefer supplier pages that keep research-use labeling, contact details, and policy pages easy to verify.

Linked supplier pages

Supplier pages that help compare naming, documentation access, batch references, and overall page clarity.

Supplier listing

Iron Peptides

This listing helps with checking naming, documentation access, storage language, and overall page clarity.

View supplier listing
10% off with code IRONMAN

Frequently Asked Questions

Common research questions about the compound, evidence base, and supplier documentation.

What is cagrilintide?

Cagrilintide is a long-acting amylin analog. Research literature on this compound is usually interpreted through mechanism, evidence level, and documentation quality.

How is amylin different from GLP-1?

Amylin and GLP-1 are different hormone systems. Amylin analogs like cagrilintide act on amylin receptor pathways tied to satiety, while GLP-1 analogs act on a separate incretin pathway, which is why the two are often studied in combination.

Why studied with semaglutide?

Cagrilintide is frequently studied alongside semaglutide because the two act on different pathways (amylin and GLP-1), and combination research explores whether pairing them produces a larger effect than either compound alone.

Is cagrilintide GLP-1?

No. Cagrilintide is an amylin analog, not a GLP-1 analog, though it is often studied alongside GLP-1 compounds like semaglutide.

What is amylin?

Amylin is a hormone co-secreted with insulin that plays a role in satiety and gastric emptying, and cagrilintide is a long-acting analog designed to mimic that activity for research purposes.

What is cagrilintide/semaglutide research?

This shorthand usually refers to research exploring cagrilintide and semaglutide together as a combination, since the two act on complementary appetite-regulating pathways.

What research areas is Cagrilintide usually linked to?

The main areas linked to Cagrilintide in this literature are obesity, appetite and satiety, combination research with semaglutide, and body-weight endpoints. Those categories reflect the published research record around the compound.

What should be verified on a Cagrilintide supplier page?

Verify identity, purity, storage guidance; avoid protocol-like combo language. In practice, that means checking batch-specific COAs, identity/purity language, research-use labeling, and overall page consistency.

How developed is the current Cagrilintide research literature?

Investigational in many contexts; track trials and publications. Trial records and literature searches are still the best way to verify where the field stands at any given point.

What makes Cagrilintide different from related compounds?

Cagrilintide is most usefully compared through mechanism and category fit. Nearby entries such as Semaglutide, Tirzepatide, Retatrutide help show how receptor logic, research emphasis, and documentation patterns differ without treating all of them as interchangeable.

References

Research entry points and source pages for verifying the broader literature.